Andera Partners announced that its portfolio company Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, closed a $138M Series C equity financing.
The financing was led by Sofinnova Partners and co-led by Intermediate Capital Group. Cédric Moreau, partner at Sofinnova Partners and Toby Sykes, managing director at ICG, will join Amolyt’s Board of Directors. In addition, new investors, funds managed by Tekla Capital Investment LLC, and CTI Life Sciences along with existing investors Andera Partners, Novo Holdings (Novo Ventures), Kurma Partners, EQT Life Sciences, Innobio 2 managed by Bpifrance Investissement, Sectoral Asset Management, Pontifax, Orbimed, Mass General Brigham Ventures, ATEM, Credit Agricole Creation and Relyens Innovation Santé/Turenne Capital, participated in the round.
Amolyt plans to use the proceeds to advance its pipeline of therapeutics for rare endocrine and related disorders, including AZP-3601, now known as eneboparatide, for the treatment of hypoparathyroidism, and AZP-3813 for the treatment of acromegaly.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
“We are very pleased to complete this large Series C financing, which will enable us to build on our momentum with eneboparatide and accelerate the growth of Amolyt Pharma and its pipeline globally,” stated Thierry Abribat, Ph.D., founder, and chief executive officer of Amolyt Pharma. “We are thankful to Sofinnova Partners and ICG for co-leading this financing round, and to all our new and existing investors for their confidence in our team and for their support of our strategy to build a global and sustainable rare disease company. This investment will allow us to continue working tirelessly on bringing novel, life-changing treatments to patients with rare endocrine and related diseases.”
Raphaël Wisniewski, partner in the Andera Life Sciences team, comments: “This exceptional financing confirms the dynamism of the life sciences sector in France and Europe today. We are delighted to participate in this round, which will enable Amolyt Pharma to make important advances in the treatment of rare endocrine diseases.”
Can’t stop reading? Read more
US Pipeline Operator ONEOK Inks Two Deals for $5.9 Billion
US pipeline operator ONEOK Inc. agreed to buy a Permian Basin rival and a controlling stake in...
Blackstone Is Said to Seek A$5.5 Billion Loan for AirTrunk Bid
Private equity firm Blackstone Inc. is in discussions with banks for a five-year loan of about...
Thrive Capital to lead multi-billion dollar OpenAI investment round at $100bn valuation
OpenAI, the company behind the popular AI tool ChatGPT, is in advanced talks to secure several...